AstraZeneca receives green light from US regulators for Alexion acquisition

Panorama of a city business district with office buildings and skyscrapers and superimposed data, charts and diagrams related to stock market, currency exchange and global finance. Blue line graphs with numbers and exchange rates, candlestick charts and financial figures fill the image with a glowing light. Sunset light.

AstraZeneca PLC (LON:AZN) said its planned acquisition of rare disease specialist Alexion Pharmaceuticals Inc has been cleared by the US Federal Trade Commission.

The FTSE 100 pharma giant said the approval follows similar clearances in Canada, Brazil, Russia and other countries globally, with additional regulatory clearances still pending from territories including the UK, the EU and Japan.

READ: What’s behind AstraZeneca’s US$39bn deal for Alexion Pharmaceuticals?

“These clearances further advance us towards closing our acquisition of Alexion. We remain focused on the next chapter for AstraZeneca and Alexion, building on our combined expertise in immunology and precision medicines and our shared ambition to bring more innovative medicines to patients worldwide. We look forward to working closely with other global authorities as we progress toward this goal”, the company’s chief financial officer and executive director Marc Dunoyer said in a statement.

AstraZeneca originally announced the deal to acquire Alexion for US$39bn in December, saying that the merger will accelerate its growing presence in immunology.

The deal will see Alexion shareholders paid US$175 for each share, made up of US$60 in cash and 2.1243 American depositary shares (ADSs), which each represent one-half of one ordinary AstraZeneca share.

Shares in AstraZeneca were down 0.2% at 7,387p in mid-afternoon trading on Friday.


Please enter your comment!
Please enter your name here